REFERENCES
1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
2. Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int 2018;38 Suppl 1:47-51.
3. Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170.
4. Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
5. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-9.
6. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:5888.
7. Targher G, Byrne CD. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology? Hepatoma Res 2020;6:64.
8. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Liver Int 2020;40:1254-61.
9. Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int 2020;40:1016-7.
10. Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020;17:387-8.
11. Dawson DA, Goldstein RB, Saha TD, Grant BF. Changes in alcohol consumption: United States, 2001-2002 to 2012-2013. Drug Alcohol Depend 2015;148:56-61.
12. Griswold MG, Fullman N, Hawley C, et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:1015-35.
13. Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
14. Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a COHORT study. Hepatology 2019;69:64-75.
15. Khoudari G, Singh A, Noureddin M, et al. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019;11:710-8.
16. Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 2018;67:2141-9.
17. Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, Bambha KM. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol 2015;49:e6-e10.
18. Lazarus JV, Ekstedt M, Marchesini G, et al. EASL International Liver Foundation NAFLD Policy Review Collaborators. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J Hepatol 2020;72:14-24.
19. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology 2021;73:1194-8.
20. Lonardo A. Renaming NAFLD to MAFLD: Could the LDE system assist in this transition? J Clin Med 2021;10:492.
21. Fouad Y, Elwakil R, Elsahhar M, et al. The NAFLD‐MAFLD debate: Eminence vs evidence. Liver Int 2021;41:255-60.
22. Polyzos SA, Kang ES, Tsochatzis EA, et al. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? Metabolism 2020;113:154413.
23. Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52.
24. Targher G. Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. Liver Int 2020;40:2879-80.
25. Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:2082-9.
26. Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int 2021;41:1290-3.
27. Wai-Sun Wong V, Lai-Hung Wong G, Woo J, et al. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31504.
28. Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 2020;40:3018-30.
29. Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31717.
30. Niriella MA, Ediriweera DS, Kasturiratne A, et al. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS One 2021;16:e0245762.
32. Mak LY, Yuen MF, Seto WK. Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". J Hepatol 2020;73:1573-4.
33. Liu D, Shen Y, Zhang R, et al. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. J Gastroenterol Hepatol 2020; doi: 10.1111/jgh.15320.
34. Fouad Y, Lazarus JV, Negro F, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther 2021;53:1080-9.
35. Zheng KI, Fan JG, Shi JP, et al. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J (Engl) 2020;133:2271-3.
36. Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. J Hepatol 2021;74:1254-6.
37. Méndez-Sánchez N, Díaz-Orozco L, Córdova-Gallardo J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. J Hepatol 2021:S0168-8278(21)00256.
38. Eslam M, George J. MAFLD: Now is the time to capitalize on the momentum. J Hepatol 2021;74:1262-3.
39. Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol 2021;74:972-4.
40. Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW. Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69.
41. Yilmaz Y. Metabolic-associated fatty liver disease: Time to integrate ground-breaking new terminology to our clinical practice? Hepatology Forum 2020;3:79-81.
42. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919.
43. Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64.
44. Mendez-sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 2021;6:65-72.
45. Spearman CW, Desalegn H, Ocama P, et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. J Hepatol 2021;74:1256-8.
46. Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021;6:73-9.
47. Clayton M, Fabrellas N, Luo J, et al. From NAFLD to MAFLD: Nurse and allied health perspective. Liver Int 2021;41:683-91.
